Discover state-of-the-art Category II wet lab space, co-loacted with world experts in vaccines and stemcells at the Royal Veterinary College's (RVC) Centre for Vaccinology and Regenerative Medicine (CVRM) in the beautiful Hertfordshire countryside.
Read more: https://www.lbic.com/lbic-cvrm
17 June 2023
Professor Ian Charles, Director of the Quadram Institute in Norwich, UK, has been recognised for a lifetime of pioneering research with an OBE (Order of the British Empire) in the King’s birthday honours.
Prof Charles has been awarded his OBE for Services to science and clinical research during a distinguished career in the biomedical sector. An internationally recognised academic scientist, entrepreneur and business leader, Ian has more than 30 years’ experience in academic and commercial research with a focus on infectious diseases, the microbiome, and…
ValiRx PLC, a life science company focused on early-stage cancer therapeutics and women’s health, has announced the acquisition of the scientific assets of Imagen Therapeutics Limited from its appointed liquidators for £170,000.
UK pharmaceutical services company Imagen offered personalised cancer treatment through the collection and use of well-characterised, patient-derived cells.
The company collected samples from patients over a number of years across a wide variety of cancers and was able to build a unique ‘biobank’ of human derived cells and provide services to the global pharmaceutical…
• Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio.
• Agreement to utilize PrecisionLife’s combinatorial analytics platform to identify genetic biomarkers that will optimize patient selection across multiple CNS clinical trials.
Oxford, UK, and Alachua, US, 15 June 2023 – PrecisionLife, a leading techbio company driving precision medicine into complex chronic diseases, and Nanopharmaceutics, Inc., a clinical-stage pharmaceutical development company, announced today a strategic collaboration aiming to accelerate and de-risk the development of…
AMSBIO is a leading provider of ready-to-use Adeno-Associated Virus (AAV) that can be engineered to efficiently deliver specific DNA sequences into target cells with a low immunogenicity.
Drawing upon years of experience – AMSBIO have developed a robust AAV Production Service providing researchers with access to the highest quality recombinant AAV vectors that can efficiently transfect multiple cell types, including dividing and non-dividing cells. These AAV vectors induce persistent gene expression in vivo without integrating into the host genome or causing any disease. These features make…
Optimer binders have been successfully developed to a novel Alzheimer’s disease biomarker
Aptamer Group CTO, Dr David Bunka, will present at Neuro-Bio’s Science Day on Optimer technology and the development of binders to support the diagnostic
York, UK (June 14, 2023) – Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, and Neuro-Bio, an Oxford-based biotechnology company with a therapeutic focus on neurodegenerative disease, announce success in the development of Optimer binders to enable a…
From streamlining R&D workflows and collaboration with data-driven software platforms, to building tools that make the development of new therapies possible, to empowering more efficient and inclusive clinical trials, companies in the tech bio space are laying the foundations for a new era of life science and digital technology innovations.
This white paper explores the ways in which tech bio is transforming the life science industry. Hear from Dr Kath Mackay, Director of Life Sciences at Bruntwood SciTech and leaders from NorthWest EHealth, Elixir Software and Cellular Highways as they…
Appointment supports growth of Metrion’s pre-clinical ion channel contract research and safety pharmacology services
Cambridge, UK, 12 June 2023: Metrion Biosciences Ltd (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of Dr Steve Jenkinson as Vice President, Drug Discovery and Safety Assessment. The US-based appointment represents an important step in the expansion of Metrion’s business, driven by its ion channel discovery capabilities.
Steve will be responsible for supporting Metrion’s growing client base across the US,…